News

Surrogate markers of nutritional status, including body mass index (BMI) and fat-free mass index, only weakly associated with lung function among children and adolescents with cystic fibrosis (CF) in a recent study. These young patients had different trajectories in nutritional status throughout childhood, with girls tending to maintain a…

Taking high-dose vitamin D supplements during acute lung infections may help to improve bone health for people with cystic fibrosis (CF). “These findings suggest that use of high-dose vitamin D supplementation during an APE [acute pulmonary exacerbation] may mitigate the bone loss suffered by people with CF with each…

An international team of scientists has published new guidelines for how best to perform exercise testing in people with cystic fibrosis (CF). “Guidance and standard operating procedures for functional exercise testing in cystic fibrosis” was published in European Respiratory Review. “Our goal is that all people…

The U.S. Food and Drug Administration (FDA) has granted fast track designation to BX004, a virus-based therapy that BiomX is developing to treat Pseudomonas aeruginosa bacterial infections in people with cystic fibrosis (CF). The FDA gives this designation to therapies that are designed to address unmet medical…

Note: This story has been updated Aug. 11, 2023, to correct the definition of a rare disease, which is defined as one affecting fewer than 200,000 people in the U.S., and to reflect that researchers estimate cystic fibrosis may affect about 160,000 people worldwide. Of the more than 100 investigational…

Treatment with Trikafta (ivacaftor/tezacaftor/elexacaftor) may help to ease a particular type of lung inflammation found in people with cystic fibrosis (CF), called a type 2 inflammatory response, that’s often associated with asthma and allergies. As asthma is reported to affect 30.8% of CF patients, a research team wondered…

A year of treatment with Kaftrio (elexacaftor/tezacaftor/ivacaftor) led to gains in lung function and nutritional status for cystic fibrosis (CF) patients in Germany, a real-world study in over 2,600 people reported. Sold as Trikafta in the U.S. and Canada, Kaftrio’s use also resulted in fewer in pulmonary exacerbations…

CFTR modulator therapies can enhance the ability of certain immune cells to kill bacteria, independent of defects in the CFTR protein that cause cystic fibrosis (CF), according to a new study. Specifically, these modulators alter metabolic processes to activate anti-bacterial processes within both CF and non-CF immune cells known…

The annual number of new cases of nontuberculous mycobacteria (NTM) lung infections is increasing in the U.S. among people with cystic fibrosis, a study finds. Between 2010 and 2019, the incidence, or new cases, of infections increased by 3.5% a year, with the highest number seen in the South. NTN…

New grants awarded by the Cystic Fibrosis Foundation will help fund 10 programs that support people impacted by cystic fibrosis (CF). The awards are being given through the foundation’s eighth annual Impact Grants, which provide as much as $10,000 for up to two years to people and nonprofit…